Chemistry:Pavinetant
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | MLE-4901; AZD-4901; AZD-2624; AZ-12472520 |
| Routes of administration | By mouth |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H25N3O3S |
| Molar mass | 459.56 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS).[1][2][3] It was also under investigation for the treatment of schizophrenia,[2] but development was discontinued for this indication due to lack of effectiveness.[1][4] In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.[1][3]
See also
References
- ↑ 1.0 1.1 1.2 "Pavinetant - Millendo Therapeutics - AdisInsight". http://adisinsight.springer.com/drugs/800038259.
- ↑ 2.0 2.1 "Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010)". Expert Opin Ther Pat 21 (5): 637–55. 2011. doi:10.1517/13543776.2011.568482. PMID 21417773.
- ↑ 3.0 3.1 "New pathways in the treatment for menopausal hot flushes". Lancet 389 (10081): 1775–1777. 2017. doi:10.1016/S0140-6736(17)30886-3. PMID 28385351.
- ↑ "The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study". J Clin Psychopharmacol 34 (2): 199–204. 2014. doi:10.1097/JCP.0000000000000071. PMID 24525659.
External links
 |  |
